A staff member displays a sample of the COVID-19 inactivated vaccine at a vaccine production plant of China National Pharmaceutical Group (Sinopharm) in Beijing, capital of China, April 10, 2020. Photo:Xinhua

An Australian research clinic said on Tuesday that it will seek volunteers to trial a COVID-19 vaccine developed by a Chinese company. The vaccine, COVID-19 S-Trimer, was developed by Clover Biopharmaceuticals, a biotechnology company based in Southwest China's Sichuan Province.

Linear Clinical Research based in Australia said in a press release that it will be recruiting healthy adults for the first phase trial within the next two months. 

If the tests are successful, the trial will be expanded globally to include thousands more participants worldwide.

Other vaccine trials have already entered their second phases. The Recombinant Novel Coronavirus Disease Vaccine (Ad5-nCoV) developed by China's Academy of Military Medical Sciences and CanSino Bio entered second phase trials on Tuesday.

A pre-clinical vaccine trial application request was submitted to the health authorities in Canada on Friday, and Health Canada accepted the request. Ad5-nCoV clinical trials will be conducted with partners in Canada after the application is approved, according to an announcement published by CanSino Bio on Monday.

Ad5-nCoV is currently undergoing phase one and phase two clinical studies in China. Over 500 healthy adults were injected with the vaccine samples and put under observation for the phase two study, said Chen Wei, a senior research fellow with China's Academy of Military Medical Sciences.